Abstract
The objective of research in the antihypertensive area, and therefore the objective of preclinical studies with potential antihypertensive drugs, is to identify therapeutic entities with: increased efficacy, decreased toxicity, increased ease and convenience of administration, an improved profile on metabolic, hemodynamic and cellular parameters, and defined and unique mechanisms of action.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams, M. A., A. Bobik, and P. I. Korner (1990). Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension 16, 252–260.
Anderson, S., H. G. Rennke, and B. M. Brenner (1986). Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J. Clin. Invest.,77, 1993–2000.
Antonaccio, M. J., B. Rubin, Z. P. Horovitz, R. J. Laffoa, M. E. Goldberg, J. P. High, D. N. Harris, and I. Zaidi (1979). Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I- converting enzyme, in spontaneously hypertensive rats. Japan J. Pharmacol.,29, 285–294.
Antonaccio, M. J., J. High, J. M. Deforrest, and E. Sybertz (1986). Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: Relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. J. Pharmacol. Exp. Ther., 238 378–387.
Bouhnik, J., F. X. Galen, J. Menard, P. Corvol, R. Seyer, J. A. Fehrentz, D. Le N’Guyen, P. Falorand, and B. Castro (1987). Production and characterization of human renin antibodies with region-oriented synthetic peptides. J. Biol. Chem., 262: 2913–2918.
Buhler, F. R., J. H. Laragh, L. Baer, E. D. Vaughan, and H. R. Brunner (1972). Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renindependent hypertensive diseases. N. Engl. J. Med., 287 1209–1214.
Gulati, O. P., and J. F. Liard (1979). Effects of propranolol in chronic two-kidney goldblatt hypertension in rats. Arch. Int. Pharmacodyn., 240 285–293.
Guyton, A. C. (1990) Personal and historical perspectives: The surprising kidney-fluid mechanism for pressure control - its infinite gain! Hypertension 16, 725–730.
Haber, E., and K. Y. Hui (1990). Specific renin inhibitors: The concept and the prospects. In J. H. Laragh, and B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 2343–2350.
Jackson, E. K. (1992). In vivo evaluation of the antagonist activity of angiotensin I analogs. J. Pharmacol. Exp. Ther.,260, 223–231.
Koike, H., K. Ito, M. Miyamoto, and H. Nishino (1980). Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 2, 299–303.
Laragh, J. H. (1978). The renin system in high blood pressure, from disbelief to reality: converting-enzyme blockade for analysis and treatment. Progress in Cardiovascular Diseases 21, 159–166.
Maxwell, M. H. (1988). Beyond blood pressure control: effect of antihypertensive therapy on cardiovascular risk factors. Am. J. Hyper.,1, 366S–371S.
McGiff, J. C., and C. P. Quilley (1981). Controversies in cardiovascular research: the rat with spontaneous genetic hypertension is not a suitable model of human essential hypertension. Circ. Res.,48, 455–463.
Schwartz, S. M., M. W. Majesky, and R. J. Dilley (1990). Vascular remodeling in hypertension and atherosclerosis. In J. H. Laragh, B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 521–539.
Stamler, J. (Comments by), and T. Kotchen (Session Chairman) (1991). Panel Discussion: Session VII. Research and Public Health Directions: Public Health and Clinical Perspectives: Is salt restriction for everyone? Hypertension 17 (Suppl I), I-216-I-221.
Sweet, C. S., P. T. Arbegast, L. S. Gaul, E. H. Blaine, and D. M. Gross (1981). Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Eur. J. Pharmacol., 76: 167–176.
Timmermans, P. B. M. W. M., D. J. Carini, A. T. Chiu, J. V. Duncia, W. A. Price, G. J. Wells, P. C. Wong, R. R. Wexler, and A. L. Johnson (1990). The discovery and physiological effects of a new class of highly specific angiotensin II-receptor antagonists. In J. H. Laragh and B. M. Brenner (Eds.), Hypertension: Pathophysiology, Diagnosis, and Management Raven Press, New York. pp. 2351–2360.
Tolins, J. P., and L. Raij (1990). Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16, 452–461.
Trippodo, N. C., and E. D. Frohlich (1981). Controversies in cardiovascular research: Similarities of genetic (spontaneous) hypertension: Man and rat. Circ. Res.,48, 309–319.
Weinberger, M. H. (1990). Clinical Conference: Optimizing cardiovascular risk reduction during antihypertensive therapy. Hypertension 16, 201–211.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Branch, R.A., Jackson, E.K. (1993). Preclinical Pharmacodynamics of Antihypertensives. In: Yacobi, A., Skelly, J.P., Shah, V.P., Benet, L.Z. (eds) Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1520-0_10
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1520-0_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1522-4
Online ISBN: 978-1-4757-1520-0
eBook Packages: Springer Book Archive